3 US Penny Stocks To Consider In February 2025

As U.S. stocks rise and Treasury yields decline following the latest Producer Price Index report, investors are cautiously optimistic about potential interest rate cuts this year. In such a market, penny stocks—typically representing smaller or newer companies—can present intriguing opportunities for growth at lower price points. While the term may seem outdated, these stocks can still offer significant potential when supported by strong financials and solid fundamentals, making them worthy of consideration for those looking to explore under-the-radar investment opportunities.

Top 10 Penny Stocks In The United States

Click here to see the full list of 711 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Perfect Moment (NYSEAM:PMNT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Perfect Moment Ltd., along with its subsidiaries, operates a fashion brand offering ski, surf, and activewear collections under the Perfect Moment name in the United States and the United Kingdom, with a market cap of $15.21 million.

Operations: The company's revenue is primarily generated through online retailers, amounting to $22.38 million.

Market Cap: $15.21M

Perfect Moment Ltd., with a market cap of US$15.21 million, faces challenges typical of penny stocks, including high volatility and financial instability. The company is not in compliance with NYSE American's equity requirements due to ongoing losses, though it plans to regain compliance by June 2026. Recent executive changes aim to leverage new leadership expertise from luxury brands like Canada Goose for expansion and profitability. Despite its unprofitability and limited cash runway, Perfect Moment is pursuing growth through strategic partnerships and retail expansions in Europe and North America, alongside efforts to enhance brand visibility and sustainability initiatives.

• Take a closer look at Perfect Moment's potential here in our financial health report.
• Explore Perfect Moment's analyst forecasts in our growth report.

Inhibitor Therapeutics (OTCPK:INTI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on developing and commercializing therapeutics for certain cancers and non-cancerous proliferation disorders in the United States, with a market cap of $11.14 million.

Operations: Currently, the company does not report any revenue segments.

Market Cap: $11.14M

Inhibitor Therapeutics, Inc., with a market cap of US$11.14 million, is pre-revenue and unprofitable but has been reducing its losses by 31.2% annually over the past five years. The company benefits from a solid financial position, as its short-term assets of US$6.5 million cover both short-term liabilities (US$44.6K) and long-term liabilities (US$3 million). While it remains debt-free, the stock exhibits high volatility despite some improvement over the past year. The management team and board are relatively inexperienced, with average tenures below industry norms, yet shareholder dilution has been minimal recently.

• Click here to discover the nuances of Inhibitor Therapeutics with our detailed analytical financial health report.
• Examine Inhibitor Therapeutics' past performance report to understand how it has performed in prior years.

Trucept (OTCPK:TREP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Trucept, Inc. operates through its subsidiaries to offer professional outsourced business services in the United States and has a market cap of $1.67 million.

Operations: The company generates revenue from its electronic security devices segment, amounting to $21.98 million.

Market Cap: $1.67M

Trucept, Inc., with a market cap of US$1.67 million, is not pre-revenue and reported third-quarter sales of US$6.16 million, up from US$4.63 million the previous year. Despite negative earnings growth over the past year and declining profit margins from 21.9% to 7.5%, the company maintains high-quality earnings and operates debt-free, with short-term assets covering both short- and long-term liabilities comfortably. The stock trades significantly below its estimated fair value but exhibits high volatility, while shareholder dilution has been minimal recently. The board is experienced with an average tenure of 4.7 years.

• Unlock comprehensive insights into our analysis of Trucept stock in this financial health report.
• Gain insights into Trucept's historical outcomes by reviewing our past performance report.

Taking Advantage

• Dive into all 711 of the US Penny Stocks we have identified here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com